Prognostically useful gene-expression profiles in acute myeloid leukemia

P. Valk, R. Verhaak, A. Beijen, C. Erpelinck, S.B. van Waalwijk van Doorn-Khosrovani, J. Boer, B. Beverloo, M. Moorhouse, P. van der Spek, B. Lowenberg, R. Delwel

Research output: Contribution to journalArticleAcademicpeer-review

825 Citations (Scopus)

Abstract

Prognostically useful gene-expression profiles in acute myeloid leukemia.

Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B, Delwel R.

Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands. p.valk@erasmusmc.nl

BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. METHODS: We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. RESULTS: Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. CONCLUSIONS: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis. Copyright 2004 Massachusetts Medical Society
Original languageEnglish
Pages (from-to)1617-1618
Number of pages2
JournalNew England Journal of Medicine
Volume350
Issue number16
DOIs
Publication statusPublished - 1 Jan 2004

Cite this

Valk, P., Verhaak, R., Beijen, A., Erpelinck, C., van Waalwijk van Doorn-Khosrovani, S. B., Boer, J., Beverloo, B., Moorhouse, M., van der Spek, P., Lowenberg, B., & Delwel, R. (2004). Prognostically useful gene-expression profiles in acute myeloid leukemia. New England Journal of Medicine, 350(16), 1617-1618. https://doi.org/10.1056/NEJMoa040465